Bo Lan

1.4k total citations
54 papers, 919 citations indexed

About

Bo Lan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Bo Lan has authored 54 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Bo Lan's work include HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (11 papers) and Cancer Treatment and Pharmacology (9 papers). Bo Lan is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (11 papers) and Cancer Treatment and Pharmacology (9 papers). Bo Lan collaborates with scholars based in China, United States and Sweden. Bo Lan's co-authors include Binghe Xu, Fei Ma, Hongnan Mo, Xuelian Chen, Jing Huang, Dawei Wu, Qing Yang, Dong Qu, Xingyuan Wang and Yang Luo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Bo Lan

48 papers receiving 906 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bo Lan China 14 619 328 173 160 150 54 919
Davide Lombardi Italy 17 609 1.0× 308 0.9× 210 1.2× 211 1.3× 96 0.6× 57 1.0k
Samanta Sarti Italy 17 490 0.8× 193 0.6× 205 1.2× 209 1.3× 112 0.7× 46 803
Ciara C. O’Sullivan United States 18 590 1.0× 262 0.8× 293 1.7× 299 1.9× 117 0.8× 72 1.0k
Ana Custodio Spain 21 705 1.1× 306 0.9× 301 1.7× 175 1.1× 107 0.7× 75 1.2k
Adrian Langleben Canada 17 725 1.2× 416 1.3× 316 1.8× 158 1.0× 103 0.7× 55 1.1k
Karim Rihawi Italy 17 452 0.7× 369 1.1× 307 1.8× 174 1.1× 113 0.8× 50 905
Constantijne H. Mom Netherlands 17 425 0.7× 221 0.7× 397 2.3× 153 1.0× 121 0.8× 57 1.1k
Concetta Elisa Onesti Italy 16 465 0.8× 287 0.9× 334 1.9× 255 1.6× 97 0.6× 58 937
Paolo Bironzo Italy 18 505 0.8× 637 1.9× 334 1.9× 191 1.2× 89 0.6× 100 1.2k
Patrizia Serra Italy 19 593 1.0× 261 0.8× 277 1.6× 244 1.5× 87 0.6× 51 1.0k

Countries citing papers authored by Bo Lan

Since Specialization
Citations

This map shows the geographic impact of Bo Lan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Lan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Lan more than expected).

Fields of papers citing papers by Bo Lan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Lan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Lan. The network helps show where Bo Lan may publish in the future.

Co-authorship network of co-authors of Bo Lan

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Lan. A scholar is included among the top collaborators of Bo Lan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Lan. Bo Lan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lan, Bo, et al.. (2025). How do economic growth and unemployment affect green development in Latin America nations?. International Review of Economics & Finance. 98. 103955–103955. 1 indexed citations
2.
Lan, Bo, Jiayu Wang, Qiao Li, et al.. (2025). The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. The Breast. 81. 104470–104470. 3 indexed citations
3.
Han, Yuhang, et al.. (2025). Single-cell sequencing exposes mast cell-derived CD52's anti-tumor action in breast cancer through the IL-6/JAK/STAT3 axis. International Journal of Biological Macromolecules. 310(Pt 3). 142879–142879.
4.
Lan, Bo, Yingying Zhang, Guohui Li, et al.. (2025). Activation of zona incerta gamma-aminobutyric acid-ergic neurons alleviates depression-like and anxiety-like behaviors induced by chronic restraint stress. World Journal of Psychiatry. 15(2). 101807–101807. 2 indexed citations
5.
6.
Liu, Shuning, Bo Lan, Yuanyi Wang, et al.. (2024). Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. EBioMedicine. 109. 105379–105379. 6 indexed citations
7.
Jiang, Mingxia, Mengqi Zhang, Yiqun Li, et al.. (2024). Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. BMC Cancer. 24(1). 1290–1290. 1 indexed citations
8.
9.
Lv, Dan, Bo Lan, Li Zhang, et al.. (2022). Association between depression and anxiety status of breast cancer patients before adjuvant chemotherapy and chemotherapy‐induced adverse events. Cancer Medicine. 12(4). 4794–4800. 8 indexed citations
10.
Lan, Bo, Dan Lv, Xiaoying Sun, et al.. (2022). Genetic Variations in IFNGR1, BDNF and IL-10 May Predict the Susceptibility to Depression and Anxiety in Chinese Women With Breast Cancer. Clinical Breast Cancer. 22(7). 674–680. 7 indexed citations
11.
Wang, Jiayu, Fei Ma, Yang Luo, et al.. (2020). Platinum‐based chemotherapy in advanced triple‐negative breast cancer: A multicenter real‐world study in China. International Journal of Cancer. 147(12). 3490–3499. 9 indexed citations
12.
Lan, Bo, Ye Lin, Jiayang Chen, et al.. (2020). Circ_0091581 Promotes the Progression of Hepatocellular Carcinoma Through Targeting miR-591/FOSL2 Axis. Digestive Diseases and Sciences. 66(9). 3074–3085. 18 indexed citations
13.
Li, Qiao, Xiuwen Guan, Shanshan Chen, et al.. (2019). Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research. 25(17). 5212–5220. 61 indexed citations
14.
Zhang, Jiaxing, Lingmin Zhang, Lingyan Fan, et al.. (2019). Evaluation of the Effectiveness of Clinical Pharmacists’ Consultation in the Treatment of Infectious Diseases: A Single-Arm, Prospective Cohort Study. Frontiers in Pharmacology. 10. 187–187. 13 indexed citations
15.
Jiang, Shiyu, Sheng Yang, Jianliang Yang, et al.. (2019). Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ Open. 9(5). e028589–e028589. 1 indexed citations
16.
Huang, Jing, Binghe Xu, Hongnan Mo, et al.. (2018). Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clinical Cancer Research. 24(6). 1296–1304. 149 indexed citations
17.
Lan, Bo, Fei Ma, Xiaoyu Zhai, et al.. (2018). The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. International Journal of Cancer. 143(1). 184–189. 27 indexed citations
18.
Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. Clinical Breast Cancer. 19(2). e370–e375. 5 indexed citations
19.
Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. International Journal of Cancer. 143(10). 2499–2504. 16 indexed citations
20.
Huang, Jing, Hongnan Mo, Dawei Wu, et al.. (2017). Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). e15572–e15572. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Davide Lombardi Breakdown of academic impact, for papers by Samanta Sarti Breakdown of academic impact, for papers by Ciara C. O’Sullivan Breakdown of academic impact, for papers by Ana Custodio Breakdown of academic impact, for papers by Adrian Langleben Breakdown of academic impact, for papers by Karim Rihawi Breakdown of academic impact, for papers by Constantijne H. Mom Breakdown of academic impact, for papers by Concetta Elisa Onesti Breakdown of academic impact, for papers by Paolo Bironzo Breakdown of academic impact, for papers by Patrizia Serra
Rankless by CCL
2026